Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma

Jun Teishima[1], Takuto Hara[1], Taisuke Tobe[1], Junichiro Hirata[1], Hideto Ueki[1], Naoto Wakita[1], Yusuke Shiraishi[1], Yasuyoshi Okamura[1], Yukari Bando[1], Tomoaki Terakawa[1], Junya Furukawa[1], Ken-ichi Harada[2], Yuzo Nakano[1], Masato Fujisawa[1]

[1]Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan; [2]Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan

Acknowledgements: *The data of mRCC patients treated with combination regimen were collected from the following affiliated institutions in addition to Kobe University Hospital; Hyogo Prefectural Amagasaki General Medical Center, Hyogo cancer Center, Japanese Red Cross Society Himeji Hospital, Kobe City Medical Center West Hospital, Hyogo Prefectural Kakogawa Medical Center, Kansa Rosai Hospital, Kita-harima Medical Center, Yodogawa Christian Hospital.*

Cite as: Teishima J, Hara T, Tobe T, et al. Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear cell renal cell carcinoma. *Can Urol Assoc J* 2024 January 30; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.8548

Published online January 30, 2024

Corresponding author: Jun Teishima, Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan; teishima@med.kobe-u.ac.jp

***

ABSTRACT

Introduction: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for metastatic non-clear-cell renal cell carcinoma (nccRCC).

Methods: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared.
Results: The first-line regimens was ICI-ICI regimens in 26 cases and ICI-TKI regimens in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between them (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535) nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups.
Conclusions: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.

INTRODUCTION

Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous subgroup of RCC, which represents 15–30% of renal tumors (1), and the prognosis of metastatic nccRCC (nccRCC) was reported to be worse compared with that of metastatic clear cell RCC (ccRCC) in the cytokine era (2). The introduction of molecular-targeted agents including tyrosine kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs) has led to the dramatic change in the treatment of metastatic RCC (mRCC) (3, 4). Regimens combining these drugs have been introduced one after another, and the prognosis of patients with mRCC has remarkably improved. Combination regimens can be broadly classified into two types: regimens combining two ICIs (ipilimumab and nivolumab) (ICI-ICI) and those combining a TKI with ICI (ICI-TKI), Four regimens have been introduced: avelumab+axitinib, pembrolizumab+axitinib, nibolumab+cabozantinib, and pembrolizumab+lenvatinib. While these regimens have been shown to improve treatment efficacy and prognosis by randomized control trials (RCTs) for mRCC with clear cell histology (5-9), patients with non-clear cell

RCC (nccRCC) have been excluded from these trials. Therefore, the benefit of various combination regimens for nccRCC remains unclear. We previously demonstrated the therapeutic efficacy of ICI-ICI therapy as a first-line option for metastatic nccRCC compared with that of TKI monotherapy (10). The aim of this study was to evaluate the therapeutic efficacy and survival benefit of combination therapy using ICI-ICI therapy or ICI-TKI therapy and to compare them.

METHODS

Patients

The 38 cases of patients with metastatic nccRCC who were treated with combination regimens consisting of ICIs and/or TKIs as first-line therapy at Kobe University Hospital or an affiliated institute in Hyogo Prefecture in Japan from January 2018 to June 2022 were retrospectively reviewed on the basis of their related clinicopathological data derived from medical records. Ethical approval was given by the Ethical Committee of Kobe University (autholization number: B230087). Patients who were treated with ipilimumab+nivolumab, and those with avelumab+axitinib, pembrolizumab+axitinib, nibolumab+cabozantinib, and pembrolizumab+lenvatinib, were defined as the ICI-ICI group and ICI-TKI group, respectively. Baseline clinical data including age,sex, pathological finding, Karnofsky performance status (KPS), metastasis status, choice of first-line regimen, and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) (11) risk were collected by reviewing medical records, and the distribution of these parameters in each group was compared. Treatment outcomes including objective response (OR) and its rate (ORR) assessed using RECIST 1.1 (12), progression-free survival (PFS) and overall survival (OS) rates, and adverse events (AEs) were evaluated in each group.

Statistical analysis

The differences in the distribution of categorical variables between the two groups were analyzed using a chi-square test. The PFS and OS rates were determined using the Kaplan-Meier method, and the differences between the two groups were analyzed using log-rank testing. All statistical analyses were conducted using Statview 5.0 software (Abacus Concepts, Inc., Berkeley, CA, USA), and p-values less than 0.05 were considered to be statistically significant.

RESULTS

The clinicopathological characteristics are listed in Table I. The median age was 70 (range, 30 to 83) years, and the median observation period was 12.6 (range, 2 to 53.7) months. The first-line regimens were ICI-ICI regimens in 26 cases and ICI-TKI ones in 10 cases. The rate of patients with liver metastasis was significantly higher and that with lymph node metastasis was significantly lower in the ICI-TKI group than those in the ICI-ICI group. There was no significant difference in patients' background between these two groups. The ORRs were 34.6 and 30.0% (p=0.9443) and disease control rates were 65.4 and 80% in the ICI-ICI and ICI-TKI groups, respectively (Table II). The 50% PFS in the ICI-TKI group was significantly longer than that in the ICI-ICI group (9.7 months and 4.6 months, p=0.0499). There was no significant difference in OS between these groups (p=0.3984) (Figure 1).

All AEs of first-line systemic therapy are listed in Table III. There was no significant difference in the frequency of occurrence between the ICI-ICI and ICI-TKI groups for any AEs below grade 2 (p=0.8535) or above grade 3 (p=0.3786). In 14 cases of ICI-ICI group (53.8%) and 8 cases of ICI-TKI group (80.0%), first-line therapy was not interrupted due to AEs (p=0.1494). Nine cases in ICI-ICI group (34.6%) and 1 case of ICI-TKI group (10%) underwent high-dose steroidal therapy for the treatment to AE (p=0.1397). In 6 cases of ICI-ICI group (23.1%) and in none of ICI-TKI group (0%), first-line therapy was terminated due to AEs (p=0.0961).

DISCUSSION

We retrospectively investigated the efficacy and safety of combination therapy including ICI-ICI and ICI-TKI as first-line therapy. ICI-TKI therapy revealed no significant difference in OS and ORR but significant longer PFS compared with ICI-ICI therapy. Although several RCTs have demonstrated the therapeutic efficacy and improved prognosis of various combination immunotherapies for mRCC (5-9), they did not include nccRCC; thus, no evidence of efficacy for nccRCC was available. Subsequently, several retrospective studies have reported the efficacy of ICI-ICI therapy for nccRCC (13–15). A study on ICI-ICI therapy for nccRCC reported that the ORR was 33.3%, while 50% of patients had progressive disease as the best response (14). Our previous study revealed similar ORRs in patients with nccRCC treated with ICI-ICI and was better than when treated with TKI as first-line therapy (10). Another study demonstrated a lower ORR for nccRCC (16). The distribution of

histological types was different among these studies, which might lead to a difference in outcome. Since nccRCC is a mixture of multiple pathologic types with very different prognoses and drug sensitivities, we should be careful when evaluating the results of various studies. ICI-ICI therapy is associated with a high incidence of serious immune-related AEs, and many patients fail to respond to ICI-ICI therapy while some patients achieve a durable response. Studies reported that the ICI-ICI regimen presented lower ORRs in patients with nccRCC than ccRCC (16, 17). ICI-TKI therapy may be expected to have a higher response rate than ICI-ICI therapy according to the data of previous RCTs for each regimen (5–9). Some TKIs have been reported to be effective for nccRCC. For example, cabozantinib showed a better outcome for papillary RCC compared with other TKIs (18). Among ICI-TKI regimens, nivolumab-cabozantinib provides 47.5% ORR for nccRCC, which consisted of 80% papillary RCC (19). In this study, we investigated patients who received ICI-TKI therapy in addition to those who received ICI-ICI therapy and compared the efficacy of these regimens in nccRCC patients. As shown in Figure 1A and Table II, ICI-TKI therapy resulted in similar ORRs but longer PFS compared with ICI-ICI therapy. In fact, ICI-TKI therapy is expected to be effective in the treatment of refractory advanced nccRCC despite the significantly higher frequency of patients with liver metastasis, which is considered to be a poor efficacy and prognostic factor (20). Although various AEs were observed, there was no significant difference in the frequency of AEs between these two regimens (Table III), suggesting that the results are acceptable in terms of safety. However, there was no significant difference in OS between the two groups, while longer PFS was observed in the ICI-TKI group (Figure 1). The rate of complete response is lower with ICI-TKI than with ICI-ICI, and it is difficult to obtain a durable response (5–9), which may explain why the difference in PFS was not reflected in OS. ICI-ICI does not include TKI in the first-line treatment, and the efficacy of TKI in the subsequent therapy has been reported (18), whereas in ICI-TKI, the choice of TKI in the subsequent therapy is limited by the first-line regimen, affecting efficacy (21, 22), which may have led to the OS results in this study. To take advantage of the high response rate and long PFS, especially when ICI-TKI is selected, appropriate consideration of local therapy, such as radiation therapy and surgical intervention including the resection of metastases and deferred cytoreductive nephrectomy during the response period, may be important to further improve prognosis.

Limitations

There were several limitations in this study. It was a small retrospective study based on the analysis of real-world data, and various histological types were mixed. Since nccRCC consists of various histological types with different genetic backgrounds and molecular features, more accumulation of precise pathological diagnosis by immunohistological and/or genetic analyses is required to establish personalized treatment for nccRCC (23). Four different types of regimens were mixed within the ICI-TKI group. The decision for the therapeutic strategy including the choice of regimen is made by individual physicians. The efficacy of treatment may differ even for the same histological type, and there have been reports on combination therapy being successfully applied to histological types that are considered refractory to treatment, such as chromophobe RCC (24) and collecting duct carcinoma (25). In addition to the various clinical trials underway for nccRCC (26), further study with a larger volume and longer follow-up period should be conducted to confirm the results from this study.

CONCLUSIONS

We demonstrated the efficacy of ICI-TKI therapy compared with ICI-ICI therapy for metastatic nccRCC. Better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group while there was no significant difference in OS. Multidisciplinary treatments with local therapy including surgery and radiation therapy might further improve the therapeutic outcomes for these regimens.

REFERENCES

1. Barthélémy P, Rioux-Leclercq N, Thibault C, et al. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. *Cancer Treat Rev* 2021;97:102191. https://doi.org/10.1016/j.ctrv.2021.102191
2. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. *J Clin Oncol* 2002;20:2376-81. https://doi.org/10.1200/JCO.2002.11.123
3. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). *J Immunother Cancer* 2019;7:354. https://doi.org/10.1186/s40425-019-0813-8
4. Pal SK, Ghate SR, Li N, et al. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-Medicare database analysis. *Clin Genitourin Cancer* 2017;15:e573-e582. https://doi.org/10.1016/j.clgc.2016.12.005
5. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med* 2018;378:1277-90. https://doi.org/10.1056/NEJMoa1712126
6. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019;380:1103-15. https://doi.org/10.1056/NEJMoa1816047
7. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019;380:1116-27. https://doi.org/10.1056/NEJMoa1816714
8. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2021;384:829-41. https://doi.org/10.1056/NEJMoa2026982
9. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med* 2021;384:1289-300. https://doi.org/10.1056/NEJMoa2035716
10. Bando Y, Furukawa J, Okamura Y, et al. Comparative efficacy of combination therapy of ipilimumab plus nivolumab for nonclear cell renal cell carcinoma. *Anticancer Res* 2022;42:973-9. https://doi.org/10.21873/anticanres.15557
11. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol* 2009;27:5794-9.

https://doi.org/10.1200/JCO.2008.21.4809

12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
13. Tachibana H, Kondo T, Ishihara H, et al. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. *Jpn J Clin Oncol* 2021;51:646-53. https://doi.org/10.1093/jjco/hyaa229
14. Gupta R, Ornstein MC, Gul A, et al. Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC). *J Clin Oncol* 2019;37:e16084. https://doi.org/10.1016/j.clgc.2019.11.012
15. McKay RR, Bossé D, Xie W,et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. *Cancer Immunol Res* 2018;6:758-65. https://doi.org/10.1158/2326-6066.CIR-17-0475
16. Tykodi SS, Gordan LN, Alter RS, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. *J Immunother Cancer* 2022;10:e003844. https://doi.org/10.1136/jitc-2021-003844
17. Izumi K, Inoue M, Washino S, et al. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. *Int J Urol* 2023;30:714-21. https://doi.org/10.1111/iju.15128
18. Pal SK, Tangen C, Thompson IMJr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment ofadvanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. *Lancet* 2021;397:695-703. https://doi.org/10.1016/S0140-6736(21)00152-5
19. Lee C-H, Voss MH, Carlo MI, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. *J Clin Oncol* 2022;40:2333-41. https://doi.org/10.1200/JCO.21.01944
20. Shinohara N, Obara W, Tatsugami K, et al. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. *Cancer Sci* 2015;106:618-26. https://doi.org/10.1111/cas.12646
21. Tomita Y, Kimura G, Fukasawa S, et al. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). *Jpn J Clin Oncol* 2021;51:966-75. https://doi.org/10.1093/jjco/hyaa266
22. Dudani S, Graham J, Wells JC, et al. First-line immuno-oncology combination

therapies in metastatic renal-cell carcinoma: results from the International Metastatic Renal-cell Carcinoma Database Consortium. *Eur Urol* 2019;76:861-7. https://doi.org/10.1016/j.eururo.2019.07.048

23. Ito K. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas. *Int J Urol* 2019;26:868-77. https://doi.org/10.1111/iju.14027
24. Fukushima T, Teishima J, Goto K, et al. Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. *Int Cancer Conf J* 2022;11:286-91. https://doi.org/10.1007/s13691-022-00561-y
25. Watanabe K, Sugiyama T, Otsuka A, et al. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. *Int Cancer Conf J* 2019;9:32-5. https://doi.org/10.1007/s13691-019-00389-z
26. Ventriglia J, Passarelli A, Pisano C, et al. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature. *Crit Rev Oncol Hematol* 2023;188:104036. https://doi.org/10.1016/j.critrevonc.2023.104036

FIGURE AND TABLES

Figure 1. (A) Progression-free survival (PFS); and (B) overall survival (OS) stratified using first-line regimens in all patients with metastatic renal cell carcinoma. ICI: immune-checkpoint inhibitors; TKI: tyrosine kinase inhibitor.



Table 1. Comparison between ICI and/or TKI groups for patients with metastatic non-clear cell RCC

	ICI-ICI (n=26) n (%)	**ICI-TKI (n=10) n (%)**	**p**	**Total (n=36) n (%)**
Age				
≥70	15 (57.7)	4 (40.0)	0.3409	19 (52.8)
≤69	11 (42.3)	6 (60.0)		17 (47.2)
Sex				
Male	19 (73.1)	8 (80.0)	0.6674	27 (75.0)
Female	7 (26.9)	2 (20.0)		9 (25.0)
Histological type				
Papillary	14 (53.8)	5 (50.0)		19 (52.8)
Chromophobe	1 (3.9)	1 (10.0)		2 5.6)
Unclassified	3 (11.5)	0 (0)		3 (8.3)
Translocated	2 (7.7)	0 (0)		2 (5.6)
Bellini duct	1 (3.9)	0 (0)		1 (2.8)
Tubulocystic	1 (3.9)	0 (0)		1 (2.8)
ACD-associated	0 (0)	2 (0)		2 (5.6)
Sarcomatoid	4 (15.4)	2 (0)		6 (16.7)
KPS				
≥80%	20 (76.9)	8 (80.0)	0.8423	28 (77.8)
<80%	6 (23.1)	2 (20.0)		8 (22.2)

No. of metastatic organs				
1	8 (30.8)	4 (40.0)	0.5987	12 (33.3)
≥2	18 (69.2)	6 (60.0)		24 (66.7)
Metastatic disease sites				
Lung	13 (50.0)	3 (30.0)	0.2794	16 (44.4)
Bone	10 (38.5)	1 (10.0)	0.0968	11 (30.6)
Lymph node	18 (69.2)	4 (40.0)	0.0171	22 (61.1)
Adrenal gland	3 (11.5)	0 (0)	0.2619	3 (8.3)
Liver	1 (3.9)	6 (60.0)	0.0001	7 (19.4)
Brain	1 (3.9)	0 (0)	0.5294	1 (2.8)
IMDC risk				
Favorable	0 (0)	1 (10.0)	0.1020	1 (2.8)
Intermediate	10 (38.5)	4 (40.0)		14 (38.9)
Poor	16 (61.5)	5 (50.0)	0.5294	21 (58.3)
Prior nephrectomy				
Radical	6 (23.1)	4 (40.0)	0.3099	10 (27.8)
Cytoreductive	8 (30.8)	2 (20.0)		10 (27.8)
Bone	12 (46.2)	4 (40.0)	0.7393	16 (44.4)
First-line regimen				
Ipilimumab + nivolumab	26 (100.0)	0 (0)		26 (72.2)
Avelumab + axitinib	0 (0)	3 (30.0)		3 (8.3)
Pembrolizumab + axitinib	0 (0)	1 (10.0)		1 (2.8)
Nivolumab + cabozantinib	0 (0)	4 (40.0)		4 (11.1)
Pembrolizumab + envatinib	0 (0)	2 (20.0)		2 (5.6)

ACD: acquired cystic disease; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; ICI: immune-checkpoint inhibitors; KPS: Karnofsky performance status; RCC: renal cell carcinoma; TKI: tyrosine kinase inhibitor.

Table 2. Objective response of first-line therapy in each regimen		
	First-line combination regimen	
	ICI-ICI	**ICI-TKI**
Objective response	(n=26), n (%)	(n=10), n (%)
CR	3 (11.5)	0 (0)
PR	6 (23.1)	3 (30.0)
SD	8 (30.8)	4 (40.0)
PD	9 (34.6)	3 (30.0)

P-values: CR: 0.2619; CR+PR: 0.7925; PD: 0.7925. CR: complete response; ICI: immune-checkpoint inhibitor; PD: progressive disease; PR: partial response; SD: stable disease; TKI: tyrosine kinase inhibitor.

Table 3. Summary of adverse events				
	ICI-ICI (n=26)		**ICI-TKI (n=10)**	
	All grades n (%)	**Grade 3–4 n (%)**	**All grades n (%)**	**Grade 3–4 n (%)**
Any event	19 (73.1)	12 (46.2)	7 (70.0)	3 (30.0)
Liver dysfunction	4 (15.4)	4 (15.4)	2 (20.0)	1 (10.0)
Renal dysfunction	1 (3.8)	1 (3.8)		
Pneumonitis	1 (3.8)	1 (3.8)		
Hypertension			3 (30.0)	
Miositis	1 (3.8)	1 (3.8)		
Skin toxicity	5 (19.2)	2 (7.7)	4 (40.0)	2 (20.0)
Dysgeusia			1 (10.0)	
Oral mucositis			1 (10.0)	
Appetite loss			1 (10.0)	
Colitis, diarrhea		1 (3.8)	3 (30.0)	
Cholangitis	1 (3.8)	1 (3.8)		
Hypopituitarism	2 (7.7)	1 (3.8)		
Adrenal insufficiency	2 (7.7)	1 (3.8)		
Hypothyroidism, thyroiditis	7 (26.9)	1 (3.8)	1 (10.0)	
Diabetes mellitus type 1		1 (3.8)		
Malaise	4 (15.4)		2 (20.0)	

ICI: immune-checkpoint inhibitor; TKI: tyrosine kinase inhibitor.